Login / Signup

Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.

Chunmei YangMixue XieKaifeng ZhangHui LiuAi-Bin LiangKen H H YoungWeidong Han
Published in: Leukemia (2020)
Keyphrases
  • cell therapy
  • hepatitis b virus
  • liver failure
  • stem cells
  • mesenchymal stem cells
  • diffuse large b cell lymphoma
  • bone marrow
  • drug induced